Tigilanol Tiglate not checked
QBiotics Group Limited · EBC-46
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.”In the company’s words, NCT05608876 on ClinicalTrials.gov
- Tested for
- Head and Neck Cancer, Soft Tissue Sarcoma
- Main trialPhase 2
- “A Phase II, open label, single arm study to assess the efficacy of intratumoural tigilanol tiglate in various head and neck solid malignancies.”In the company’s words, NCT05608876 on ClinicalTrials.gov
- Other names
- EBC-46
Other drugs for Head and Neck Cancer
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- BupiZengeOncoZenge AB · Phase 3
- KC1036Beijing Konruns Pharmaceutical Co., Ltd. · Phase 3
- APG-157Aveta Biomics, Inc. · Phase 3
Coming up1
- Jan 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 31 Jul 2025 | A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer | |
| Phase 2Recruiting | Jan 2027 | A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma | |
| Phase 2Terminated | 18 Jul 2022 | A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma | |
| Phase 1/2Terminated | 12 Jul 2022 | A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026